1
|
Fujiki H, Matsunaga M, Furukawa M, Yamashita T, Nakamura S, Miyazaki T, Mizuguchi H, Menjo Y, Matsuda T, Yamada Y. In vitro and in vivo pharmacological profile of OPC-61815, a water-soluble phosphate ester pro-drug of tolvaptan. J Pharmacol Sci 2022; 150:163-172. [DOI: 10.1016/j.jphs.2022.08.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2022] [Revised: 07/21/2022] [Accepted: 08/25/2022] [Indexed: 10/31/2022] Open
|
2
|
Huang S, Dong R, Xu G, Liu J, Gao X, Yu S, Qie P, Gou G, Hu M, Wang Y, Peng J, Guang B, Xu Y, Yang T. Synthesis, Characterization, and In Vivo Evaluation of Desmethyl Anethole Trithione Phosphate Prodrug for Ameliorating Cerebral Ischemia-Reperfusion Injury in Rats. ACS OMEGA 2020; 5:4595-4602. [PMID: 32175506 PMCID: PMC7066653 DOI: 10.1021/acsomega.9b04129] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/04/2019] [Accepted: 02/12/2020] [Indexed: 06/10/2023]
Abstract
Anethol trithione (ATT) has a wide range of physiological activities, but its use is limited due to its poor water solubility. To improve the solubility of ATT, we synthesized and characterized a novel phosphate prodrug (ATXP) relying on the availability of the hydroxy group in 5-(4-hydroxyphenyl)-3H-1,2-dithiole3-thione (ATX), which was transformed from ATT rapidly and extensively in vivo. Our results showed that ATXP significantly improved drug solubility. ATXP was rapidly converted to ATX and reached a maximum plasma concentration with a T max of approximately 5 min after intravenous (iv) administration. Furthermore, after the oral administration of ATXP, the C max was 3326.30 ± 566.50 ng/mL, which was approximately 5-fold greater than that of the parent drug form, indicating that ATXP has greater absorption than that of ATT. Additionally, the oral phosphate prodrug ATXP increased the ATX in the area under the plasma concentration vs time curves (AUC0-t = 3927.40 ± 321.50 and AUC0-∞ = 4579.0 ± 756.30), making its use in practical applications more meaningful. Finally, compared to the vehicle, ATXP was confirmed to maintain the bioactivity of the parent drug for a significant reduction in infarct volume 24 h after reperfusion. Based on these findings, the phosphate prodrug ATXP is a potentially useful water-soluble prodrug with improved pharmacokinetic properties.
Collapse
Affiliation(s)
- Sheng Huang
- School
of Pharmacy, Chengdu Medical College, No. 783, Xindu Avenue, Xindu District, Chengdu 610500, Sichuan, China
| | - Renhan Dong
- School
of Pharmacy, Chengdu Medical College, No. 783, Xindu Avenue, Xindu District, Chengdu 610500, Sichuan, China
- Chengdu
Beinuokecheng Biotechnology Co., Ltd., No. 88, Keyuan South Road, New and High-Tech Zone, Chengdu 610094, Sichuan, China
| | - Gaojie Xu
- School
of Pharmacy, Chengdu Medical College, No. 783, Xindu Avenue, Xindu District, Chengdu 610500, Sichuan, China
| | - Jin Liu
- School
of Pharmacy, Chengdu Medical College, No. 783, Xindu Avenue, Xindu District, Chengdu 610500, Sichuan, China
| | - Xiaofang Gao
- School
of Pharmacy, Chengdu Medical College, No. 783, Xindu Avenue, Xindu District, Chengdu 610500, Sichuan, China
| | - Siqi Yu
- School
of Pharmacy, Chengdu Medical College, No. 783, Xindu Avenue, Xindu District, Chengdu 610500, Sichuan, China
| | - Pengfan Qie
- School
of Pharmacy, Chengdu Medical College, No. 783, Xindu Avenue, Xindu District, Chengdu 610500, Sichuan, China
| | - Gang Gou
- School
of Pharmacy, Chengdu Medical College, No. 783, Xindu Avenue, Xindu District, Chengdu 610500, Sichuan, China
| | - Min Hu
- School
of Pharmacy, Chengdu Medical College, No. 783, Xindu Avenue, Xindu District, Chengdu 610500, Sichuan, China
| | - Yu Wang
- School
of Pharmacy, Chengdu Medical College, No. 783, Xindu Avenue, Xindu District, Chengdu 610500, Sichuan, China
| | - Jian Peng
- School
of Pharmacy, Chengdu Medical College, No. 783, Xindu Avenue, Xindu District, Chengdu 610500, Sichuan, China
| | - Bing Guang
- School
of Pharmacy, Chengdu Medical College, No. 783, Xindu Avenue, Xindu District, Chengdu 610500, Sichuan, China
- Chengdu
Beinuokecheng Biotechnology Co., Ltd., No. 88, Keyuan South Road, New and High-Tech Zone, Chengdu 610094, Sichuan, China
| | - Ying Xu
- The
First Affiliated Hospital, Chengdu Medical College, Chengdu 610500, Sichuan, China
| | - Tai Yang
- School
of Pharmacy, Chengdu Medical College, No. 783, Xindu Avenue, Xindu District, Chengdu 610500, Sichuan, China
| |
Collapse
|
3
|
Xu G, Dong R, Liu J, Zhao L, Zeng Y, Xiao X, An J, Huang S, Zhong Y, Guang B, Yang T. Synthesis, characterization and in vivo evaluation of honokiol bisphosphate prodrugs protects against rats' brain ischemia-reperfusion injury. Asian J Pharm Sci 2019; 14:640-648. [PMID: 32104490 PMCID: PMC7032162 DOI: 10.1016/j.ajps.2018.11.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Revised: 10/16/2018] [Accepted: 11/03/2018] [Indexed: 01/01/2023] Open
Abstract
Honokiol (HK) usage is greatly restricted by its poor aqueous solubility and limited oral bioavailability. We synthesized and characterized a novel phosphate prodrug of honokiol (HKP) for in vitro and in vivo use. HKP greatly enhanced the aqueous solubility of HK (127.54 ± 15.53 mg/ml) and the stability in buffer solution was sufficient for intravenous administration. The enzymatic hydrolysis of HKP to HK was extremely rapid in vitro (T1/ 2 = 8.9 ± 2.11 s). Pharmacokinetics studies demonstrated that after intravenous administration of HKP (32 mg/kg), HKP was converted rapidly to HK with a time to reach the maximum plasma concentration of ∼5 min. The prodrug HKP achieved an improved T1/2 (7.97 ± 1.30 h) and terminal volume of distribution (26.02 ± 6.04 ml/kg) compared with direct injection of the equimolar parent drug (0.66 ± 0.01 h) and (2.90 ± 0.342 ml/kg), respectively. Furthermore, oral administration of HKP showed rapid and improved absorption compared with the parent drug. HKP was confirmed to maintain the bioactivity of the parent drug for ameliorating ischemia-reperfusion injury by decreasing brain infarction and improving neurologic function. Taken together, HKP is a potentially useful aqueous-soluble prodrug with improved pharmacokinetic properties which may merit further development as a potential drug candidate.
Collapse
Affiliation(s)
- Gaojie Xu
- Chengdu Medical College, Chengdu 610500, China
| | - Renghan Dong
- Chengdu Yishan Biotechnology Co., Ltd., Chengdu 610094, China
| | - Jin Liu
- Chengdu Medical College, Chengdu 610500, China
| | - Li Zhao
- Chengdu Medical College, Chengdu 610500, China
| | - Yan Zeng
- Chengdu Medical College, Chengdu 610500, China
| | | | - Jinglin An
- Chengdu Medical College, Chengdu 610500, China
| | - Sheng Huang
- Chengdu Medical College, Chengdu 610500, China
| | | | - Bing Guang
- Chengdu Medical College, Chengdu 610500, China
- Chengdu Yishan Biotechnology Co., Ltd., Chengdu 610094, China
| | - Tai Yang
- Chengdu Medical College, Chengdu 610500, China
| |
Collapse
|